Rejected by US regulators in February, Amryt Pharma's butterfly skin therapy Filsuvez has been recommended in Europe to the delight of the Irish firm and patients with the rare and devastating hereditary disorder.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval...






